In the long search for ways to slow Alzheimer's disease, science has often focused on reducing the production of amyloid beta — the protein that accumulates into toxic plaques in the aging brain. Now, researchers at St. Jude Children's Research Hospital have found that the body may already carry its own answer: a naturally occurring protein called midkine that actively prevents those plaques from forming. Published this week in Nature Structural & Molecular Biology, the discovery reframes midkine's mysterious rise in Alzheimer's patients not as a symptom, but as a defense — one that scientists
Midkine protein shown to block Alzheimer's amyloid assembly in breakthrough study
Midkine breaks apart the very structures that cause Alzheimer's
Mark
So midkine is already in the brain—why isn't it stopping Alzheimer's in patients who have the disease?
Mimi
That's the crucial question. The protein is there and accumulating, but something about its presence or function isn't enough to prevent the disease. The researchers haven't yet addressed whether the problem is insufficient midkine, or whether amyloid beta somehow overwhelms it, or if there are other factors at play.
Mark
The mouse models without midkine showed more amyloid buildup. But do we know what happens in human brains that develop Alzheimer's despite having midkine?
Mimi
Not from this study. They've shown the mechanism works in controlled conditions, but the human disease is far more complex. There could be other proteins, inflammatory processes, or genetic factors that override midkine's protective effect.
Mark
If they design a drug that mimics midkine, would it work better than the protein itself?
Mimi
Potentially. A synthetic molecule could be engineered to bind more tightly, persist longer in the brain, or avoid being broken down. But first they need to understand the exact binding site and mechanism—that's the next phase of work.
Mark
How far away is a treatment?
Mimi
This is foundational science. They've identified a mechanism and a target. Drug development from here typically takes years of testing in animal models, then clinical trials. This isn't a treatment yet—it's a direction.
Mark
Why does midkine accumulate in Alzheimer's brains if it's supposed to be protective?
Mimi
That's the paradox the field will need to solve. It could be that the brain is trying to compensate, ramping up midkine production as amyloid accumulates. Or it could be that midkine accumulates but becomes ineffective. The answer will matter for how you design a treatment.
O Pulso
- Amyloid beta plaques are a defining feature of Alzheimer's disease, and despite decades of research, no treatment has successfully stopped them from forming in the brain.
- St. Jude researchers discovered that midkine — a protein already elevated in Alzheimer's patients — physically disrupts amyloid beta at two critical stages of assembly, preventing both initial clumping and the expansion of plaques.
- Multiple molecular techniques confirmed the finding: when midkine was introduced to amyloid beta assemblies, fluorescent tracers that light up in the presence of plaques went dark — the structures were being dismantled.
- Mouse models with the midkine gene deleted showed dramatically accelerated amyloid accumulation, proving the protein's role is protective, not incidental.
- The research team is now working to map the precise molecular interaction between midkine and amyloid beta, with the goal of designing small-molecule drugs that could replicate its protective effect in human patients.
In the long search for ways to slow Alzheimer's disease, science has often focused on reducing the production of amyloid beta — the protein that accumulates into toxic plaques in the aging brain. Now, researchers at St. Jude Children's Research Hospital have found that the body may already carry its own answer: a naturally occurring protein called midkine that actively prevents those plaques from forming. Published this week in Nature Structural & Molecular Biology, the discovery reframes midkine's mysterious rise in Alzheimer's patients not as a symptom, but as a defense — one that scientists now hope to replicate in drug form.
In the brain of an Alzheimer's patient, amyloid beta proteins clump into toxic plaques — a process long considered one of the disease's defining and most damaging features. Scientists at St. Jude Children's Research Hospital have now identified a natural protein that appears to stop this process: midkine, a small growth factor whose levels rise in Alzheimer's patients for reasons that had, until now, remained unexplained.
The study, published in Nature Structural & Molecular Biology, is the first to demonstrate that midkine actively protects against amyloid buildup. Led by structural biologist Junmin Peng, the team used an array of molecular tools — including fluorescence assays, electron microscopy, and nuclear magnetic resonance spectroscopy — to show that midkine physically interferes with amyloid beta at two critical stages: the initial elongation of protein chains and the secondary nucleation that allows plaques to spread.
The evidence was difficult to dismiss. A fluorescent tracer designed to illuminate amyloid assemblies went dark when midkine was introduced — and reappeared when it was removed — indicating the protein was actively breaking apart the structures. The most striking confirmation came from mouse models: animals engineered without the midkine gene showed dramatically higher amyloid accumulation, revealing that the protein normally functions as a protective shield.
Midkine is already known to science as a growth factor active during fetal development and as a biomarker in cancer research, where it is frequently overexpressed. Its role in neurodegeneration, however, had gone largely unexplored. That gap is now closing. Peng's team is focused on mapping the precise molecular interaction between midkine and amyloid beta, hoping to design drugs that mimic its protective mechanism — offering a new therapeutic direction that targets not the production of amyloid beta, but its assembly into the structures that destroy the brain.
In the brain of an Alzheimer's patient, amyloid beta proteins clump together into toxic assemblies—a hallmark of the disease that drives neurodegeneration. Scientists at St. Jude Children's Research Hospital have now identified a natural brake on this process: a protein called midkine that appears to prevent those dangerous clusters from forming in the first place.
The discovery, published this week in Nature Structural & Molecular Biology, represents the first clear demonstration that midkine actively protects against Alzheimer's. Researchers have long known that midkine levels rise in the brains of Alzheimer's patients, but the reason remained mysterious. The new work reveals the mechanism: midkine physically interferes with amyloid beta assembly, stopping the protein from sticking together and accumulating into the plaques that characterize the disease.
Junmin Peng, a structural biologist at St. Jude, led the investigation using an arsenal of molecular techniques—fluorescence assays, electron microscopy, nuclear magnetic resonance, and circular dichroism—to map exactly how midkine and amyloid beta interact. The team worked with disease models engineered to replicate the amyloid buildup seen in human Alzheimer's brains. What they found was striking: midkine doesn't just slow the assembly process; it actively breaks apart the growing chains of amyloid beta at two critical stages of formation, preventing both the initial elongation and the secondary nucleation that allows plaques to expand.
To prove this wasn't mere correlation, the researchers used a fluorescent tracer called thioflavin T that lights up when amyloid beta forms large assemblies. When midkine was present, the signal weakened and eventually vanished—evidence that the protein was dismantling the very structures the tracer was designed to detect. When they added midkine to the mix, the signal returned, confirming that the protein was actively inhibiting assembly. Nuclear magnetic resonance spectroscopy, which can only detect small molecules, showed the same pattern: the signal disappeared as amyloid beta grew into large clumps, but reappeared when midkine was introduced, indicating the protein was breaking those clumps apart.
The most compelling evidence came from mouse models. When researchers deleted the midkine gene entirely, the animals showed dramatically higher levels of amyloid beta assemblies—a clear sign that the protein normally acts as a protective shield. Without it, the toxic accumulation accelerated unchecked.
Midkine itself is a small, multifunctional growth factor that appears abundantly during fetal development and continues to play roles in normal cell growth throughout life. Its involvement in cell proliferation has made it a known biomarker in cancer research, where it is often overexpressed. But its connection to neurodegeneration had remained largely unexplored until now.
The implications for drug development are substantial. Peng and his team are now focused on understanding precisely how midkine binds to amyloid beta—the molecular handshake that allows it to disrupt assembly. If they can map that interaction in detail, they could design small-molecule drugs that mimic midkine's protective effect, potentially offering a new therapeutic strategy for slowing or preventing Alzheimer's progression. The work opens a pathway that researchers can now pursue: not blocking amyloid beta production, but rather preventing it from assembling into the toxic structures that damage the brain.
Citações Notáveis
We want to continue to understand how this protein binds to amyloid beta so we can design small molecules to do the same thing.— Junmin Peng, St. Jude Children's Research Hospital
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Health & Medicine